BMY Bristol Myers Squibb Co
- Stocks
- Healthcare
- NYSE: BMY
Price (delayed)
$46.47
Market cap
$94.6B
P/E Ratio
15.65
Dividend/share
$2.48
EPS
$2.97
Enterprise value
$127.85B
Relative Growth:
Rel. Growth:
60
Relative Strength:
Rel. Strength:
31
Relative Valuation:
Rel. Valuation:
89
Relative Profitability:
Rel. Profitability:
97
Bristol Myers Squibb is an American pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease,
Highlights
Bristol Myers Squibb's EPS has surged by 183% YoY and by 19% QoQ
The net income has surged by 183% year-on-year and by 20% since the previous quarter
The gross margin has decreased by 7% YoY
Bristol Myers Squibb's gross profit has decreased by 6% YoY
Key stats
What are the main financial stats of BMY
Market
Valuations
Earnings
Shares outstanding
2.04B
Market cap
$94.6B
Enterprise value
$127.85B
Price to earnings (P/E)
15.65
Price to book (P/B)
5.1
Price to sales (P/S)
1.97
PEG
0.09
EV/EBIT
15.93
EV/EBITDA
9.88
EV/Sales
2.66
Revenue
$48.03B
Gross profit
$33.38B
Operating income
$8.03B
Net income
$6.04B
EBIT
$8.03B
EBITDA
$12.94B
Free cash flow
$15.3B
Per share
Balance sheet
Liquidity
EPS
$2.97
EPS diluted
$2.96
Free cash flow per share
$7.52
Book value per share
$9.11
Revenue per share
$23.6
TBVPS
$26.86
Total assets
$96.89B
Total liabilities
$78.29B
Debt
$48.98B
Equity
$18.55B
Working capital
$7.49B
Debt to equity
2.64
Current ratio
1.27
Quick ratio
0.99
Net debt/EBITDA
2.57
Margins
Efficiency
Dividend
EBITDA margin
26.9%
Gross margin
69.5%
Net margin
12.6%
Operating margin
16.7%
Return on assets
6.4%
Return on equity
34.7%
Return on invested capital
13%
Return on capital employed
11.7%
Return on sales
16.7%
Dividend yield
5.34%
DPS
$2.48
Payout ratio
83.5%
BMY stock price
How has the Bristol Myers Squibb stock price performed over time
Intraday
1.93%
1 week
9.08%
1 month
2.24%
1 year
-16.94%
YTD
-17.84%
QTD
3.04%
Financial performance
How have Bristol Myers Squibb's revenue and profit performed over time
Revenue
$48.03B
Gross profit
$33.38B
Operating income
$8.03B
Net income
$6.04B
Gross margin
69.5%
Net margin
12.6%
The net income has surged by 183% year-on-year and by 20% since the previous quarter
BMY's net margin has soared by 182% year-on-year and by 19% since the previous quarter
The operating income rose by 22% since the previous quarter
The operating margin has increased by 21% since the previous quarter
Price vs fundamentals
How does BMY's price correlate with its fundamentals
Growth
What is Bristol Myers Squibb's growth rate over time
Valuation
What is Bristol Myers Squibb stock price valuation
P/E
15.65
P/B
5.1
P/S
1.97
EV/EBIT
15.93
EV/EBITDA
9.88
EV/Sales
2.66
Bristol Myers Squibb's EPS has surged by 183% YoY and by 19% QoQ
BMY's P/B is 16% below its last 4 quarters average of 6.1 but 4.1% above its 5-year quarterly average of 4.9
Bristol Myers Squibb's equity has increased by 8% YoY and by 6% from the previous quarter
The price to sales (P/S) is 30% less than the 5-year quarterly average of 2.8 and 10% less than the last 4 quarters average of 2.2
Efficiency
How efficient is Bristol Myers Squibb business performance
The ROE has soared by 196% YoY and by 17% from the previous quarter
Bristol Myers Squibb's ROA has soared by 184% YoY and by 19% from the previous quarter
BMY's return on invested capital is up by 24% since the previous quarter
Bristol Myers Squibb's return on sales has increased by 21% QoQ
Dividends
What is BMY's dividend history
DPS
$2.48
Dividend yield
5.34%
Payout ratio
83.5%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Bristol Myers Squibb financials performed over time
BMY's total assets is 24% greater than its total liabilities
The quick ratio has increased by 18% YoY and by 9% QoQ
Bristol Myers Squibb's current ratio has increased by 5% from the previous quarter and by 2.4% YoY
BMY's debt is 164% greater than its equity
The company's debt to equity fell by 9% YoY and by 6% QoQ
Bristol Myers Squibb's equity has increased by 8% YoY and by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.